-范恩柯尔生物科技（中山）有限公司

FC084 : First In Class&Best In Class highly selective Axl inhibitors will officially launch Phase II clinical trials in August 2024, in combination with trastuzumab for immune unresponsive non-small cell lung cancer patients.

----------------------------------------------------------------------------------------------

◎ AXL's Key Role in Tumors

Belongs to the TAM receptor tyrosine kinase family

Inhibits immune responses of APCs, T cells, macrophages and NK cells

Associated with tumor EMT, proliferation, migration and survival

◎ FC084 Project Highlights

Modulates the tumor local microenvironment and promotes the infiltration of T lymphocytes, especially CD8+ effector T lymphocytes

The first project in China to enter clinical trials

Clinical study led by Professor Zhou Caicun, a renowned lung cancer expert and President of the International Association for the Study of Lung Cancer (IASLC), as Principal Investigator (PI)

----------------------------------------------------------------------------------------------

Product Pipeline In Progress Product - Precision Tumor Immune Pipeline In Progress Product - Radioactive Nuclide Coupled Drug Pipeline InnoRDC Platform Technology